Incannex Healthcare Inc (NASDAQ: IXHL) is a clinical-stage pharmaceutical company developing drug candidates that have not yet generated commercial revenue. The company has no established revenue stream as of the fiscal year ended June 30, 2025, and funds operations through financing activities rather than product sales. As of June 30, 2025, Incannex held $15.0 million in cash and cash equivalents, up from $5.9 million as of June 30, 2024, and reported net cash outflows from operating activities of $12.5 million for FY2025, a reduction of $3.3 million compared to FY2024. The company trades on the Nasdaq Capital Market under the symbol IXHL, having transferred from the Nasdaq Global Market effective July 10, 2025. As of September 28, 2025, there were 347,705,507 shares of common stock outstanding held by approximately 4,657 stockholders of record. Incannex has never declared or paid a cash dividend and intends to retain any earnings for operations. The company qualifies as a smaller reporting company as of December 31, 2024.

Revenue model

No commercial revenue as of FY2025. Operations are funded through financing arrangements. The company has not yet established an ongoing source of revenue sufficient to cover operating and capital expenditure requirements, per the 10-K filed 2025-09-29.

Products and services

Clinical-stage drug candidates in development. Specific product names and pipeline details are not supported by the filing excerpts provided.

Customers and end markets

No commercial customers as of FY2025. End markets are not specified in the filing excerpts provided.

Value-chain role

Pre-commercial drug developer. The company conducts clinical trials through partner research laboratories and is subject to FDA, MHRA, EMA, and other regulatory approval processes before any product can be marketed.

Geographic exposure

Intends to initiate clinical studies in countries other than the United States. Subject to FCPA and international anti-corruption regulations. UK regulatory exposure under the MHRA framework and Windsor Framework effective January 1, 2025. Specific country-level revenue allocation is not applicable given pre-revenue status.

Source: SEC 10-K, filed 2025-09-29

Industry: Pharmaceutical Preparations Peers: Eli Lilly and Co